Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS	17	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	18	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus
NEWS	19	MAY 23	GBFULL enhanced with patent drawing images
NEWS	20	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	21	MAY 26	STN User Update to be held June 6 and June 7 at the SLA 2005 Annual Conference

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:30:54 ON 26 MAY 2005

=> fil reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:31:02 ON 26 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 MAY 2005 HIGHEST RN 851163-60-5
DICTIONARY FILE UPDATES: 25 MAY 2005 HIGHEST RN 851163-60-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10009567.str



chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15

```
chain bonds :
9-10  10-11  11-12
ring bonds :
1-2  1-6  1-13  2-3  3-4  4-5  4-7  5-6  5-9  6-14  7-8  8-9  13-15  14-15
exact/norm bonds :
1-2  1-6  1-13  2-3  3-4  4-5  4-7  5-6  5-9  6-14  7-8  8-9  9-10  10-11  11-12
13-15  14-15
isolated ring systems :
containing 1 :


G1:C,O,S

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:CLASS  12:CLASS  13:Atom  14:Atom  15:Atom



L1       STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1                STR
```




```
G1 C,O


Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 12:33:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   2734 TO ITERATE

 36.6% PROCESSED    1000 ITERATIONS                                  2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        51544 TO    57816
PROJECTED ANSWERS:               2 TO      249

L2             2 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:33:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  53443 TO ITERATE
```

100.0% PROCESSED 53443 ITERATIONS 57 ANSWERS
SEARCH TIME: 00.00.01

L3 57 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10009567.str



chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15
chain bonds :
9-10 10-11 11-12
ring bonds :
1-2 1-6 1-13 2-3 3-4 4-5 4-7 5-6 5-9 6-14 7-8 8-9 13-15 14-15
exact/norm bonds :
1-2 1-6 1-13 2-3 3-4 4-5 4-7 5-6 5-9 6-14 7-8 8-9 9-10 10-11 11-12
13-15 14-15
isolated ring systems :
containing 1 :

G1:C,O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom

L4 STRUCTURE UPLOADED

=> d
L4 HAS NO ANSWERS
L4 STR



G1 C,O,S

Structure attributes must be viewed using STN Express query preparation.

```
=> s l4
SAMPLE SEARCH INITIATED 12:34:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   5390 TO ITERATE

 18.6% PROCESSED    1000 ITERATIONS                                1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       103398 TO   112202
PROJECTED ANSWERS:               1 TO      246

L5            1 SEA SSS SAM L4

=> s l4 full
FULL SEARCH INITIATED 12:34:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 107190 TO ITERATE

100.0% PROCESSED  107190 ITERATIONS                             33 ANSWERS
SEARCH TIME: 00.00.01

L6            33 SEA SSS FUL L4

=> s l6 and caplus/lc
      46453380 CAPLUS/LC
L7           32 L6 AND CAPLUS/LC

=> s l6 not l7
L8            1 L6 NOT L7

=> d
```

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 767271-64-7 REGISTRY
ED Entered STN: 22 Oct 2004
CN 1H-Thieno[2,3-g]indole-1-ethanamine, 7-chloro- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H11 Cl N2 S
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              331.25     331.46

FILE 'CAPLUS' ENTERED AT 12:35:04 ON 26 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 26 May 2005  VOL 142 ISS 22
FILE LAST UPDATED: 25 May 2005  (20050525/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l7
L9          10 L7

=> d ibib abs hitstr 1-10
```

L9 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:303324 CAPLUS
DOCUMENT NUMBER: 141:54150
TITLE: Indoline derivatives as 5-HT2C receptor agonists
AUTHOR(S): Bentley, J. M.; Adams, D. R.; Bebbington, D.; Benwell, K. R.; Bickerdike, M. J.; Davidson, J. E. P.; Dawson, C. E.; Dourish, C. T.; Duncton, M. A. J.; Gaur, S.; George, A. R.; Giles, P. R.; Hamlyn, R. J.; Kennett, G. A.; Knight, A. R.; Malcolm, C. S.; Mansell, H. L.; Misra, A.; Monck, N. J. T.; Pratt, R. M.; Quirk, K.; Roffey, J. R. A.; Vickers, S. P.; Cliffe, I. A.
CORPORATE SOURCE: Vernalis Research Ltd, Wokingham, RG41 5UA, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(9), 2367-2370
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:54150
GI



I

AB A series of 1-(1-indolinyl)-2-propylamines was synthesized and evaluated as 5-HT2C receptor agonists for the treatment of obesity. The general methods of synthesis of the precursor indoles are described. The functional efficacy and radioligand binding data for all of the compds. at 5-HT2 receptor subtypes are reported. A number of compds., including (αS)-6-Bromo-α-methyl-1H-indole-1-ethanamine (VER-3323) (I), were found to reduce food intake in rats after oral administration.

IT **327183-18-6P**, VER-5584
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(VER-5584; preparation of chiral α-methyl-1H-indole-1-ethanamine derivs. and study of their activity as 5-HT2C receptor agonists and antiobesity agents)

RN 327183-18-6 CAPLUS
CN 1H-Furo[2,3-g]indole-1-ethanamine, 2,3,7,8-tetrahydro-α-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:716279 CAPLUS
DOCUMENT NUMBER: 137:232679
TITLE: Preparation of piperazines as selective serotonin 5-HT2 receptor ligands for the treatment of obesity and other disorders
INVENTOR(S): Hebeisen, Paul; Mattei, Patrizio; Muller, Marc; Richter, Hans; Roever, Stephan; Taylor, Sven
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.; Vernalis Research Limited
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072584	A2	20020919	WO 2002-EP2443	20020306
WO 2002072584	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2438596	AA	20020919	CA 2002-2438596	20020306
EP 1370561	A2	20031217	EP 2002-732459	20020306
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002008111	A	20040302	BR 2002-8111	20020306
JP 2004532823	T2	20041028	JP 2002-571500	20020306
US 2002169163	A1	20021114	US 2002-92751	20020307
US 6844345	B2	20050118		
PRIORITY APPLN. INFO.:			GB 2001-6177	A 20010313
			WO 2002-EP2443	W 20020306

OTHER SOURCE(S): MARPAT 137:232679
GI



I



II



III



IV

L9 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AB Title compds. I [R1-R4 = H, halo, OH, etc. with the proviso that at least one of the moieties R1-R4 is not H; R5 = H, alkyl, cycloalkyl; R6 = H, alkyl, cycloalkyl, etc.; R7 = H, halo, alkyl, etc.], their pharmaceutically acceptable salts and formulations were prepared For example, LAH reduction of amide II, prepared from oxathiazolidine III and 7-ethyl-1H-indole-2-carboxylic acid Et ester, afforded claimed piperazine IV in 100% yield. In serotonin receptor binding assays, piperazine IV exhibited activity toward the 5-HT2c, 5-HT2b and 5-HT2a receptors with ki values of 50, 86 and 205 nM, resp. Also compds. I have functional activity at the human 5-HT2c receptor in the range of 10,000 to 0.1 nM. Compds. I are claimed for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, etc. (no data provided).

IT **459817-56-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of piperazines as selective serotonin 5-HT2 receptor ligands for the treatment of obesity and other disorders)

RN 459817-56-2 CAPLUS
CN Cyclopent[g]indole-2-carboxylic acid, 1-[(1R)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-methylethyl]-1,6,7,8-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:137191 CAPLUS
DOCUMENT NUMBER: 134:193338
TITLE: Preparation and use of condensed indoline derivatives and their use as 5-HT, in particular 5-HT2c, receptor ligands
INVENTOR(S): Roffey, Jonathan Richard Anthony; Davidson, James Edward Paul; Mansell, Howard Langham; Hamlyn, Richard John; Adams, David Reginald
PATENT ASSIGNEE(S): Vernalis Research Limited, UK
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012602	A1	20010222	WO 2000-GB3008	20000804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2377637	AA	20010222	CA 2000-2377637	20000804
BR 2000013314	A	20020402	BR 2000-13314	20000804
EP 1202964	A1	20020508	EP 2000-951696	20000804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200200351	T2	20020621	TR 2002-200200351	20000804
JP 2003507366	T2	20030225	JP 2001-517500	20000804
AU 774337	B2	20040624	AU 2000-64554	20000804
ZA 2001010218	A	20021212	ZA 2001-10218	20011212
PRIORITY APPLN. INFO.:			GB 1999-18965 A	19990811
			WO 2000-GB3008 W	20000804

OTHER SOURCE(S): MARPAT 134:193338
GI



I



II

AB Novel compds. I and use thereof are claimed [wherein; R1, R2 are H, alkyl; R3 is alkyl; R4, R5 are H, alkyl; R6, R7 are H, halo, OH, alkyl, aryl, NH2, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, alkylsulfonyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 327183-08-4 CAPLUS
CN Cyclopent[g]indole-1(2H)-ethanamine, 3,6,7,8-tetrahydro-α-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327183-09-5 CAPLUS
CN Cyclopent[g]indole-1(2H)-ethanamine, 3,6,7,8-tetrahydro-α-methyl-, (αS)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 327183-08-4
CMF C14 H20 N2

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

carboxyl; A is a 5- or 6-membered (un)satd. (hetero)cycle (n is 1 or 2)]. Eleven examples are given. The synthesis of II proceeded by alkylation of benz[g]indole with the corresponding N-tert-butoxycarbonyl-protected sidechain. The resulting indole was converted to the indoline with sodium cyanoborohydride in acetic acid. Deprotection with trifluoroacetic acid furnished II as an oil and isolation of a solid as its hemi-fumarate deriv. Compds. I showed affinity for 5-HT2A, 5-HT2B and 5-HT2C receptors in a CHO cell line. Compd. II had a Ki of 107 nM in a radiolabeled [3H]-5-HT assay. Treatment of disorders of the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly the treatment of obesity are claimed uses of compds. I.

IT 327182-99-0P 327183-00-6P 327183-08-4P
327183-09-5P 327183-10-8P 327183-11-9P
327183-12-0P 327183-13-1P 327183-17-5P
327183-18-6P 327185-05-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and use of condensed indoline derivs. and their use as 5-HT receptor ligands)

RN 327182-99-0 CAPLUS
CN 1H-Thieno[2,3-g]indole-1-ethanamine, 2,3,7,8-tetrahydro-α-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327183-00-6 CAPLUS
CN 1H-Thieno[2,3-g]indole-1-ethanamine, 2,3,7,8-tetrahydro-α-methyl-, (αS)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 327182-99-0
CMF C13 H18 N2 S

Absolute stereochemistry.



L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 327183-10-8 CAPLUS
CN 1H-Furo[2,3-g]indole-1-ethanamine, 3-ethyl-2,3,7,8-tetrahydro-α-methyl-, (αS,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327183-11-9 CAPLUS
CN 1H-Furo[2,3-g]indole-1-ethanamine, 3-ethyl-2,3,7,8-tetrahydro-α-methyl-, (αS,3R)-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 327183-10-8
CMF C15 H22 N2 O

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 327183-12-0 CAPLUS
CN 1H-Furo[2,3-g]indole-1-ethanamine, 3-ethyl-2,3,7,8-tetrahydro-α-

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
methyl-, (αS,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327183-13-1 CAPLUS
CN 1H-Furo[2,3-g]indole-1-ethanamine, 3-ethyl-2,3,7,8-tetrahydro-α-methyl-, (αS,3S)-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 327183-12-0
CMF C15 H22 N2 O

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 327183-17-5 CAPLUS
CN 1H-Furo[2,3-g]indole-1-ethanamine, 2,3,7,8-tetrahydro-α-methyl-, dihydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●2 HCl

RN 327183-18-6 CAPLUS
CN 1H-Furo[2,3-g]indole-1-ethanamine, 2,3,7,8-tetrahydro-α-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327185-05-7 CAPLUS
CN 1H-Furo[2,3-g]indole-1-ethanamine, 2,3,7,8-tetrahydro-α-methyl-, (αS)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 327183-18-6
CMF C13 H18 N2 O

Absolute stereochemistry.



CM 2

CRN 110-17-8

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CMF C4 H4 O4

Double bond geometry as shown.



IT **327183-27-7P 327183-28-8P 327183-51-7P**
327183-52-8P 327183-62-0P 327183-63-1P
327183-66-4P 327183-67-5P 327183-68-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and use of condensed indoline derivs. and their use as 5-HT receptor ligands)
RN 327183-27-7 CAPLUS
CN Carbamic acid, [(1S)-2-(7,8-dihydro-1H-furo[2,3-g]indol-1-yl)-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327183-28-8 CAPLUS
CN Carbamic acid, [(1S)-1-methyl-2-(2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327183-51-7 CAPLUS
CN Carbamic acid, [(1S)-2-(7,8-dihydro-1H-thieno[2,3-g]indol-1-yl)-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 327183-52-8 CAPLUS
CN Carbamic acid, [(1S)-1-methyl-2-(2,3,7,8-tetrahydro-1H-thieno[2,3-g]indol-1-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327183-62-0 CAPLUS
CN Carbamic acid, [(1S)-2-(7,8-dihydrocyclopent[g]indol-1(6H)-yl)-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327183-63-1 CAPLUS
CN Carbamic acid, [(1S)-1-methyl-2-(3,6,7,8-tetrahydrocyclopent[g]indol-1(2H)-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 327183-66-4 CAPLUS
CN Carbamic acid, [(1S)-2-(3-ethyl-7,8-dihydro-1H-furo[2,3-g]indol-1-yl)-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327183-67-5 CAPLUS
CN Carbamic acid, [(1S)-2-[(3R)-3-ethyl-2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327183-68-6 CAPLUS
CN Carbamic acid, [(1S)-2-[(3S)-3-ethyl-2,3,7,8-tetrahydro-1H-furo[2,3-

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
g]indol-1-yl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:183599 CAPLUS
DOCUMENT NUMBER: 132:289039
TITLE: Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptors
AUTHOR(S): Browning, Christopher; Beresford, Isabel; Fraser, Neil; Giles, Heather
CORPORATE SOURCE: Receptor Pharmacology Glaxo Wellcome Medicines Research Centre, Stevenage, SG1 2NY, UK
SOURCE: British Journal of Pharmacology (2000), 129(5), 877-886
CODEN: BJPCBM; ISSN: 0007-1188
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The authors have pharmacol. characterized recombinant human mt1 and MT2 receptors, stably expressed in Chinese hamster ovary cells (CHO-mt1 and CHO-MT2), by measurement of [3H]-melatonin binding and forskolin-stimulated cAMP production [3H]-melatonin bound to mt1 and MT2 receptors with pKD values of 9.89 and 9.56 and Bmax values of 1.20 and 0.82 pmol mg-1 protein, resp. While most melatonin receptor agonists had similar affinities for mt1 and MT2 receptors, a number of putative antagonists had substantially higher affinities for MT2 receptors, including luzindole (11-fold), GR128107 (23-fold) and 4-P-PDOT (61-fold). In both CHO-mt1 and CHO-MT2 cells, melatonin inhibited forskolin-stimulated accumulation of cAMP in a concentration-dependent manner (pIC50 9.53 and 9.74, resp.) causing 83 and 64% inhibition of cAMP production at 100 nM, resp. The potencies of a range of melatonin receptor agonists were determined At MT2 receptors, melatonin, 2-iodomelatonin and 6-chloromelatonin were essentially equipotent, while at the mt1 receptor these agonists gave the rank order of potency of 2-iodomelatonin > melatonin > 6-chloromelatonin. In both CHO-mt1 and CHO-MT2 cells, melatonin-induced inhibition of forskolin-stimulated cAMP production was antagonized in a concentration-dependent manner by the melatonin receptor antagonist luzindole, with pA2 values of 5.75 and 7.64, resp. Melatonin-mediated responses were abolished by pre-treatment of cells with pertussis toxin, consistent with activation of Gi/Go G-proteins. This is the first report of the use of [3H]-melatonin for the characterization of recombinant mt1 and MT2 receptors. The authors' results demonstrate that these receptor subtypes have distinct pharmacol. profiles.

IT 170729-12-1, GR196429
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(pharmacol. characterization of human recombinant melatonin mt1 and MT2 receptors)

RN 170729-12-1 CAPLUS
CN Acetamide, N-[2-(2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:765097 CAPLUS
DOCUMENT NUMBER: 132:31090
TITLE: Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude
AUTHOR(S): Drijfhout, Willem J.; De Vries, Jan B.; Homan, Evert J.; Brons, Helsen F.; Copinga, Swier; Gruppen, Gert; Beresford, Isabel J. M.; Hagan, Russell M.; Grol, Cor J.; Westerink, Ben H. C.
CORPORATE SOURCE: University Centre for Pharmacy, Department of Medicinal Chemistry, University of Groningen, Groningen, 9713, Neth.
SOURCE: European Journal of Pharmacology (1999), 382(3), 157-166
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In this study the authors have examined the ability of melatonin and four synthetic melatonin receptor agonists to entrain endogenous melatonin secretion in rats, free running in constant darkness. The circadian melatonin profile was measured by transpineal microdialysis, which not only reveals the time of onset and end of production (phase), but also the amplitude of the rhythm. Exogenous melatonin given at the onset of subjective darkness (clock time 12 h) was effective to entrain endogenous melatonin production Only one agonist, 2-chloroacetamido-8-methoxytetralin (AH-017), mimicked this action. Two other agonists, 4-methoxy-2-(methylene propylamide)indan (GG-012) and N-[2-[2,3,7,8-tetrahydro-1 H-furo(2,3-g)indol-1-yl]ethyl]acetamide (GR196429), induced a phase-delay under free running conditions, possibly by increasing tau (τ) period. One agonist, 2-acetamido-8-methoxytetralin (AH-001) did not show any phase effect on the free running rhythm. Unexpectedly, all melatonin receptor agonists increased the amplitude of melatonin secretion. The amount of the increase varied from just below the level of significance (AH-001) to an approx. 2-fold increase (GG-012 and GR196429). This is in clear contrast to entrainment with melatonin, which significantly decreased the amplitude. It is hypothesized that entrainment and effects on amplitude of melatonin secretion are mediated by different mechanisms which can be differentially modulated using specific ligands.

IT 170729-12-1, GR196429
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase amplitude)

RN 170729-12-1 CAPLUS
CN Acetamide, N-[2-(2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:7974 CAPLUS
DOCUMENT NUMBER: 130:66493
TITLE: Preparation of tricyclic pyrrole or pyrazole derivatives as pharmaceuticals with affinity for the 5HT2c receptors
INVENTOR(S): Maeno, Kyoichi; Kazuta, Ken-ichi; Kubota, Hideki; Shimada, Itsuro; Kimizuka, Tetsuya; Sakamoto, Shuichi; Wanibuchi, Fumikazu
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9856768	A1	19981217	WO 1998-JP2579	19980611
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9869893	A1	19981217	AU 1998-69893	19980603
AU 727654	B2	20001221		
TW 502024	B	20020911	TW 1998-87108930	19980605
CA 2291651	AA	19981217	CA 1998-2291651	19980611
AU 9876740	A1	19981230	AU 1998-76740	19980611
EP 990650	A1	20000405	EP 1998-924579	19980611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
RU 2191176	C2	20021020	RU 1998-111511	19980611
JP 3410478	B2	20030526	JP 1999-502097	19980611
CN 1203234	A	19981230	CN 1998-114746	19980612
CN 1097054	B	20021225		
BR 9802005	A	20000321	BR 1998-2005	19980612
MX 9804743	A	20000831	MX 1998-4743	19980612
US 6245796	B1	20010612	US 1999-445104	19991202
PRIORITY APPLN. INFO.:			JP 1997-157255 A	19970613
			WO 1998-JP2579 W	19980611

OTHER SOURCE(S): MARPAT 130:66493
GI



I



II

L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AB The title compds. I [ring Y represents an unsatd. 5-membered ring optionally having 1 to 3 heteroatoms of one or more types selected from the group consisting of nitrogen, oxygen and sulfur or an unsatd. 6-membered ring having 1 or 2 nitrogen atoms; X represents a bond or carbon; the dotted line represents a double or single bond; V represents nitrogen or CH; and A represents linear or branched lower alkylene optionally substituted by halogeno or cycloalkyl; R1, R2 = H, alkyl; or NR1R2 = N-containing saturated heterocyclic ring; R3, R4 = H, alkyl, etc.; R5 - R9 = H, alkyl, OH, etc.; a proviso is given] are prepared I have high selectivity and affinity for 5-HT2c receptors and are useful in treating central nervous system diseases such as sexual function disorder, appetite regulation disorder, anxiety, depression or sleep disturbance. In an in vitro test for affinity for the 5HT2c receptor, the indazole derivative II showed the Ki value of 0.8 nM.

IT 217523-12-1P, 1H-Thieno[2,3-g]indole-1-ethanamine
217634-55-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic pyrrole or pyrazole derivs. as pharmaceuticals with affinity for 5HT2c receptors)

RN 217523-12-1 CAPLUS
CN 1H-Thieno[2,3-g]indole-1-ethanamine (9CI) (CA INDEX NAME)



RN 217634-55-4 CAPLUS
CN 1H-Thieno[2,3-g]indole-1-ethanamine, 7-chloro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:727253 CAPLUS
DOCUMENT NUMBER: 130:47746
TITLE: Pharmacological characterization of melatonin mt1 receptor-mediated stimulation of [35S]-GTPγS binding
AUTHOR(S): Beresford, Isabel J. M.; Harvey, Fiona J.; Hall, David A.; Giles, Heather
CORPORATE SOURCE: Receptor Pharmacology, Glaxo Wellcome Medicines Research Centre, Stevenage, SG1 2NY, UK
SOURCE: Biochemical Pharmacology (1998), 56(9), 1167-1174
CODEN: BCPCA6; ISSN: 0006-2952
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The activation of G-proteins by melatonin mt1 receptors was studied by measuring [35S]-guanosine-5'-(3-thiotriphosphate) ([35S]-GTPγS) binding to membranes prepared from Chinese hamster ovary (CHO) cells stably expressing human mt1 receptors. Melatonin stimulated [35S]-GTPγS binding in a concentration-dependent manner (pEC50, 8.77±0.02). The optimal (212±4%) increase over basal levels of binding (basal = 100%) was observed following incubation of membranes (12.5 μg protein/well) for 120 min at 30° with [35S]-GTPγS (0.1 nM), in the presence of GDP (10 μM), NaCl (100 mM), and MgCl2 (10 mM). Melatonin analogs stimulated [35S]-GTPγS binding with a rank order (2-iodomelatonin > melatonin = S20098 > GR196429>6-chloromelatonin = 6-hydroxymelatonin » N-acetylserotonin ≥ GR135531 = mt1 luzindole = 5-HT = 0), which was identical to their affinities for the high affinity state of the receptor (correlation coefficient 0.94). All agonists evoked similar maximum increases in [35S]-GTPγS binding. EC50 values were 14- to 63-fold lower than binding affinities. The melatonin receptor antagonist luzindole (0.1-10 μM) evoked a parallel rightward shift in the melatonin concentration-response curve, with a pKB of 7.19±0.13, which is similar to its affinity in radioligand binding studies for human mt1 receptors. Stimulation of [35S]-GTPγS binding was abolished by pretreatment of cells with pertussis toxin (18 h, 100 ng/mL) prior to preparation of membranes. Melatonin was without effect in CHO cells which lacked the mt1 receptor. Thus, melatonin and melatonin analogs stimulate [35S]-GTPγS binding with a profile which is consistent with binding to mt1 receptors causing activation of Gi/Go G-proteins.

IT 170729-12-1, GR196429
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(melatonin and melatonin analogs stimulate [35S]-GTPγS binding with a profile which is consistent with binding to mt1 receptors causing activation of Gi/Go G-proteins)
RN 170729-12-1 CAPLUS
CN Acetamide, N-[2-(2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:394595 CAPLUS
DOCUMENT NUMBER: 129:117807
TITLE: GR196429: a nonindolic agonist at high-affinity melatonin receptors
AUTHOR(S): Beresford, Isabel J. M.; Browning, Christopher; Starkey, Sarah J.; Brown, Jason; Foord, Steven M.; Coughlan, Josephine; North, Peter C.; Dubocovich, Margarita L.; Hagan, Russell M.
CORPORATE SOURCE: Medicines Research Centre, Glaxo Wellcome Research and Development, Ltd., Hertfordshire, UK
SOURCE: Journal of Pharmacology and Experimental Therapeutics (1998), 285(3), 1239-1245
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English

AB N-[2-[2,3,7,8-tetrahydro-1H-furo(2,3-g)indol-1-yl]ethyl]acetamide (GR196429) is a novel, nonindolic melatonin receptor agonist. GR196429 had high affinity for human mt1 (pKi 9.9) and MT2 (pKi 9.8) receptors expressed in Chinese hamster ovary cells and for 2-[125I]-iodomelatonin binding sites in human cerebellum, guinea pig superior colliculus and hypothalamus and chicken retina and tectum (pKi 8.8-9.5). GR196429 was inactive at a wide range of other hormone and neurotransmitter receptors. In Chinese hamster ovary cells expressing human mt1 or MT2 receptors, both melatonin and GR196429 dose-dependently inhibited forskolin-stimulated cAMP accumulation. In rabbit isolated retina, GR196429 inhibited calcium-dependent [3H]-dopamine release with potency (IC50 30 pM) and maximum effect (76±5% at 1 nM) similar to those of melatonin. The response was antagonized by the melatonin receptor antagonist luzindole (1 μM). In slices of rat brain suprachiasmatic nucleus, perfusion (1 h) with GR196429 at zeitgeber time 10 phase advanced the circadian peak in neuronal activity measured on the following day, with a maximum phase advance of 2.7±0.3 h at 10 pM and an EC50 of 0.6 pM, results that indicated a melatonin-like action on the phase of the circadian clock. CNS penetration and duration of receptor occupancy was determined in an ex vivo radioligand binding assay. In membranes of guinea pig superior colliculus prepared 30 min after administration of GR196429 (s.c.), 2-[125I]-iodomelatonin binding was inhibited with an ED50 of 0.04 mg/kg. After a dose of 1 mg/kg, binding was significantly inhibited for at least 3 h. Thus GR196429 is a potent and selective agonist at high-affinity melatonin receptors, which modulates circadian rhythms in an in vitro model of the circadian clock and which readily penetrates the CNS.

IT 170729-12-1, GR196429
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(GR196429 as a nonindolic agonist at high-affinity melatonin receptors)
RN 170729-12-1 CAPLUS
CN Acetamide, N-[2-(2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:220137 CAPLUS
DOCUMENT NUMBER: 127:1057
TITLE: Melatonin receptor antagonists that differentiate between the human Mella and Mellb recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor
AUTHOR(S): Dubocovich, Margarita L.; Masana, Monica I.; Iacob, Stanca; Sauri, Daniel M.
CORPORATE SOURCE: Med. Sch., Northwestern University Chicago, Chicago, IL, 60611, USA
SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (1997), 355(3), 365-375
CODEN: NSAPCC; ISSN: 0028-1298
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Subtype-selective agonists, partial agonists, and antagonists which distinguish the human recombinant Mella and Mellb melatonin receptors expressed in COS-7 cells were identified. Melatonin receptor agonists showed higher affinity for competition of 2-[125I]-iodomelatonin binding for the Mellb than the Mella melatonin receptor. The dissociation consts. (Ki) of 16 agonists determined on the recombinant human Mella and Mellb melatonin receptor subtypes showed a correlation. Six agonists showed 10-60-fold higher affinity for the Mellb melatonin receptor as indicated by the affinity selectivity ratios (Mella/Mellb). Dissociation consts. for competition of 11 partial agonists and antagonists for 2-[125I]-iodomelatonin binding were 15.5-362-fold higher for the Mellb than for the Mella melatonin receptor. The lack of correlation between the pKi values strongly suggest that the 2 human melatonin receptor subtypes can be distinguished pharmacol. The partial agonist 5-methoxyluzindole and the competitive melatonin receptor antagonists GR128107, 4-phenyl-2-chloroacetamidotetraline, 4-phenyl-2-acetamidotetraline, and 4-phenyl-2-propionamidotetraline are selective Mellb melatonin receptor analogs as their affinity selectivity ratios (Mella/Mellb) are >100. It is concluded that the 40% overall amino acid difference in the sequence of the human recombinant Mella and Mellb melatonin receptors is reflected in distinct pharmacol. profiles for the subtypes. The pharmacol. profile of the presynaptic ML1 melatonin heteroreceptor of rabbit retina mediating inhibition of the Ca-dependent release of dopamine was compared to that of the recombinant Mella and Mellb melatonin receptors. Melatonin inhibited [3H]dopamine release by 50% (IC50) at 20 pM with a maximal inhibitory effect (80%) at 1 nM. The partial agonists showed various degrees of efficacy while none of the competitive melatonin receptor antagonists did inhibit [3H]dopamine release on their own. The potency (IC50) of full melatonin receptor agonists correlated with their affinity to compete for 2-[125I]-iodomelatonin binding to either the Mella or Mellb human melatonin receptors. The apparent dissociation consts. (KB) for partial agonists and antagonists to antagonize the inhibition of [3H]dopamine release mediated by activation of the ML1 heteroreceptor by melatonin, correlated with the affinity consts. (Ki) for 2-[125I]-iodomelatonin binding determined on the Mellb but not the Mella subtype. These results demonstrate that the pharmacol. profile of the human recombinant Mellb melatonin receptor is similar to that of the functional presynaptic melatonin heteroreceptor of rabbit retina, which is referred as an ML1 subtype. It is concluded that the selective Mellb melatonin partial agonists and antagonists described here can be used to identify melatonin receptor subtypes in native tissues and to search for subtype selective analogs with therapeutic potential.

IT 170729-12-1, GR 196429

L9 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(pharmacol. profile of rabbit retina ML1 presynaptic heteroreceptor by melatonin receptor antagonists distinguishing human recombinant Mella and Mellb subtypes)
RN 170729-12-1 CAPLUS
CN Acetamide, N-[2-(2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:943453 CAPLUS
DOCUMENT NUMBER: 123:340087
TITLE: Preparation of indolines which are melatonin receptor agonists and antagonists
INVENTOR(S): North, Peter Charles; Carter, Malcolm Clive
PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9517405	A1	19950629	WO 1994-EP4220	19941220
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9410056	A	19951018	ZA 1994-10056	19941219
CA 2179402	AA	19950629	CA 1994-2179402	19941220
AU 9512743	A1	19950710	AU 1995-12743	19941220
AU 684877	B2	19980108		
EP 736028	A1	19961009	EP 1995-903817	19941220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
IL 112097	A1	19980615	IL 1994-112097	19941221
US 5633276	A	19970527	US 1996-652460	19960614
PRIORITY APPLN. INFO.:			GB 1993-26192 A	19931222
			WO 1994-EP4220 W	19941220

OTHER SOURCE(S): MARPAT 123:340087
GI



I

AB The title compds. [I; R1 = H, halogen, C1-6 alkyl; R2 = CR3R4(CH2)pNR5COR6; R3-R5 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-7 cycloalkyl; p = 1-4; n = 2-4], useful as melatonin receptor agonists and antagonists in the treatment of conditions associated with a disturbed functioning of the melatonin system [i.e., jet lag (no data), osteoporosis (no data), CNS disorders (no data), etc. (no data)], are prepared and I-containing formulations presented. Thus, 2-(5-chloro-2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethylamine was amidated with Ac2O, producing N-[2-(5-chloro-2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]acetamide, m.p. 147-149°, which demonstrated a IC50 against the binding of melatonin to rabbit retina of 0.004 nM.

L9 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
IT 170729-12-1P 170729-13-2P 170729-14-3P
170729-15-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolines which are melatonin receptor agonists and antagonists)
RN 170729-12-1 CAPLUS
CN Acetamide, N-[2-(2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 170729-13-2 CAPLUS
CN Acetamide, N-[2-(2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 170729-14-3 CAPLUS
CN Cyclopropanecarboxamide, N-[2-(2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 170729-15-4 CAPLUS
CN Acetamide, N-[2-(5-chloro-2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-

yl)ethyl]- (9CI) (CA INDEX NAME)



IT 170728-97-9P 170728-98-0P 170728-99-1P
170729-08-5P 170729-09-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indolines which are melatonin receptor agonists and antagonists)

RN 170728-97-9 CAPLUS
CN 1H-Furo[2,3-g]indole-1-acetonitrile, 2,3,7,8-tetrahydro- (9CI) (CA INDEX NAME)



RN 170728-98-0 CAPLUS
CN 1H-Furo[2,3-g]indole-1-acetonitrile, 7,8-dihydro- (9CI) (CA INDEX NAME)



RN 170728-99-1 CAPLUS
CN 1H-Furo[2,3-g]indole-1-ethanamine, 7,8-dihydro- (9CI) (CA INDEX NAME)



RN 170729-08-5 CAPLUS
CN 1H-Furo[2,3-g]indole-1-acetonitrile, 5-chloro-7,8-dihydro- (9CI) (CA INDEX NAME)



RN 170729-09-6 CAPLUS
CN 1H-Furo[2,3-g]indole-1-ethanamine, 5-chloro-7,8-dihydro- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	49.85	381.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.30	-7.30

STN INTERNATIONAL LOGOFF AT 12:35:26 ON 26 MAY 2005